Timing of CSL's Change of CFO Queried by Bull -- Market Talk

Dow Jones

10/01

2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. "In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026," analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20. (david.winning@wsj.com)

(END) Dow Jones Newswires

September 30, 2025 18:54 ET (22:54 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572083133"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572083133\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572083133?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 06:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572083133","market":"fut","top_or_hot":-1,"title":"Timing of CSL's Change of CFO Queried by Bull -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  (david.winning@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 30, 2025 18:54 ET (22:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Timing of CSL's Change of CFO Queried by Bull -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTiming of CSL's Change of CFO Queried by Bull -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-01 06:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  (david.winning@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 30, 2025 18:54 ET (22:54 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2572083133","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572083133","pubTimestamp":1759272840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7508":"医药生物股","STRK":"MICROSTRATEGY 8.00% SERIES A PERPETUAL STRIKE PFD","CSL":"卡莱尔伙伴","BK4516":"特朗普概念","BK4086":"建筑产品","CSL.AU":"CSL LIMITED","BK4596":"哈里斯概念","BK7511":"ESG概念","BK4600":"加密货币概念","BK4588":"碎股","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7067":"生物科技","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK4595":"比特币概念","BK7501":"新冠治疗股","BK4023":"应用软件"},"translate_title":"牛市议论质疑CSL更换首席财务官的时机","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL":1.5,"CSL.AU":0.9,"STRK":0.6},"content_text":"2250 GMT [Dow Jones]--Citi is slightly puzzled by the timing of pharmaceutical company CSL's CFO change. CSL says Joy Linton will step down as CFO on Oct. 7. She will be succeeded by Chief Strategy Officer Ken Lim and there will be a supporting transition period. \"In our experience, major management change is unusual in the run-up to a big restructuring event like CSL's proposed spin-off of Seqirus, anticipated in 2H of FY 2026,\" analyst Laura Sutcliffe says. Citi assumes that Lim was heavily involved with the decision to spin off the vaccines business. It sees the personnel change as an opportunity for CSL to refresh goals and potentially higher-level strategy over time. Citi has a buy call and A$265.00/share price target on CSL, which ended Tuesday at A$198.20.  (david.winning@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 30, 2025 18:54 ET (22:54 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}